🟢 OTLK is trading 1.8% up today after FDA sets July 2026 decision date for Lytenava

OTLK is trading 1.8% up at $1.73 in pre-market trading following enthusiasm around the FDA’s July 29, 2026, PDUFA date for its eye drug Lytenava.

• The FDA accepted the resubmitted Biologics License Application (BLA) as a Class 1 review, establishing a definitive timeline for the company’s primary drug candidate.
• The move extends a sharp rally from last week, as investors react to the setting of a key binary catalyst for the biotech firm.